Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
Department of Orthopedics, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
Medicine (Baltimore). 2023 Sep 8;102(36):e34926. doi: 10.1097/MD.0000000000034926.
To analyze the prognostic value of fibrinogen-albumin ratio (FAR) in predicting the overall survival in elderly osteosarcoma patients. One hundred nineteen elderly osteosarcoma patients (> 40 years old) from 2 centers were retrospectively reviewed and analyzed. The cutoff values of the biomarker were calculated via receiver operating characteristic curves, and the cohort was divided into high FAR group and low FAR group. The association between the FAR and clinical-pathological parameters was analyzed. And the prognosis of elderly osteosarcoma patients and the potential risk factors were analyzed using Kaplan-Meier method and Cox proportional hazards model. Finally, a clinical nomogram was constructed, and its predictive capacity was verified. According to receiver operating characteristic results, the cutoff value for FAR was 0.098, and the enrolled patients were divided into the low FAR group and high FAR group. The FAR was significantly correlated with several clinical-pathological characteristics, including age, tumor size, tumor stage, recurrence, and metastasis. Moreover, the multivariate Cox analyses results showed that the FAR, pathological fracture, and metastasis were independent risk factors for overall survival in elderly osteosarcoma patients. The predictive nomogram was subsequently constructed, representing satisfactory predictive performance for prognosis in elderly patients with osteosarcoma. The FAR value is a promising indicator for elderly osteosarcoma patients, which is correlated with the various clinical characteristics and prognosis. A clinical nomogram integrating FAR and other clinical indicators is a convenient and available tool to assess the prognosis and manage the individualized and precise treatment of elderly patients with osteosarcoma.
分析纤维蛋白原-白蛋白比值（FAR）对预测老年骨肉瘤患者总生存期的预后价值。回顾性分析来自 2 个中心的 119 例老年骨肉瘤患者（>40 岁）。通过受试者工作特征曲线计算生物标志物的临界值，并将队列分为高 FAR 组和低 FAR 组。分析 FAR 与临床病理参数之间的关系。采用 Kaplan-Meier 方法和 Cox 比例风险模型分析老年骨肉瘤患者的预后及其潜在危险因素。最后，构建临床列线图，并验证其预测能力。根据受试者工作特征结果，FAR 的截断值为 0.098，将入组患者分为低 FAR 组和高 FAR 组。FAR 与年龄、肿瘤大小、肿瘤分期、复发和转移等多个临床病理特征显著相关。此外，多因素 Cox 分析结果表明，FAR、病理性骨折和转移是老年骨肉瘤患者总生存期的独立危险因素。随后构建了预测列线图，对老年骨肉瘤患者的预后具有良好的预测性能。FAR 值是老年骨肉瘤患者有前途的指标，与各种临床特征和预后相关。一个整合 FAR 和其他临床指标的临床列线图是评估老年骨肉瘤患者预后和管理个体化和精确治疗的便捷有效工具。
